Development of Clinical-Grade Antibodies against Tumor-Specific Mutations to Target Neuroblastoma

CONCLUSION: We describe a new strategy to make customized antibodies for individual cancer patients and present the data required to meet FDA specifications to begin a phase I clinical trial.PMID:35777796

Source: Annals of Clinical and Laboratory Science - July 1, 2022 Category: Laboratory Medicine Authors: Stephanie C Pero Abhinav B Nagulapally Linda Mei Fan Zhang Giselle S Sholler David N Krag Girja S Shukla Source Type: research